Patents by Inventor Marisa P. Dolled-Filhart

Marisa P. Dolled-Filhart has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CORRELATION OF MOLECULAR MARKERS WITH CLINICAL OUTCOME IN GBM PATIENTS RADIATION TREATED WITH OR WITHOUT GEFITINIB
    Publication number: 20140142101
    Abstract: Interestingly, for prognosis, the significant biomarkers for Gefitinib-treated GBM patients (RTOG 0211) appeared to differ compared to historical, RT and non-Gefitinib-treated GBM patients. In Gefitinib-treated patients, those with higher levels of nuclear pAKT driven by PTEN loss, higher levels of nuclear pMAPK, and lower levels of nuclear pmTOR had significantly worse clinical outcomes. In contrast, in non-Gefitinib-treated patients, patients with PTEN-deficiency, and higher levels of EGFRvIII, total EGFR, IGFR1, NFkB and lower levels of nuclear Survivin appeared to have adverse clinical outcomes, highlighting the treatment-dependency of these biomarkers.
    Type: Application
    Filed: October 14, 2013
    Publication date: May 22, 2014
    Applicants: Radiation Therapy Oncology Group of the Americal College of Radiology, HistoRx, Inc.
    Inventors: Arnab CHAKRAVARTI, Robert Pinard, Donald Waldron, Agnes Ang, Marisa P. Dolled-Filhart, Annette Molinaro
  • Correlation of molecular markers with clinical outcome in GBM patients radiation treated with or without gefitinib
    Patent number: 8557527
    Abstract: Interestingly, for prognosis, the significant biomarkers for Gefitinib-treated GBM patients (RTOG 0211) appeared to differ compared to historical, RT and non-Gefitinib-treated GBM patients. In Gefitinib-treated patients, those with higher levels of nuclear pAKT driven by PTEN loss, higher levels of nuclear pMAPK, and lower levels of nuclear pmTOR had significantly worse clinical outcomes. In contrast, in non-Gefitinib-treated patients, patients with PTEN-deficiency, and higher levels of EGFRvIII, total EGFR, IGFR1, NFkB and lower levels of nuclear Survivin appeared to have adverse clinical outcomes, highlighting the treatment-dependency of these biomarkers.
    Type: Grant
    Filed: September 22, 2009
    Date of Patent: October 15, 2013
    Assignees: HistoRx, Inc., Radiation Therapy Oncology Group of the American College of Radiology
    Inventors: Arnab Chakravarti, Robert Pinard, Agnes Ang, Marisa P. Dolled-Filhart, Annette Molinaro, Alpana Waldron
  • Methods for determining signal transduction activity in tumors
    Patent number: 8497080
    Abstract: The method of the invention pertains to determining signal transduction activity in a tissue section by immunohistochemistry techniques. The expression level of the receptor of interest is determined as well as the expression levels of one or more effector molecules of the receptor signal transduction pathway. Furthermore a combined ratio of expression levels of effector molecules in subcellular compartments with the receptor expression was found to have prognostic significance.
    Type: Grant
    Filed: February 5, 2013
    Date of Patent: July 30, 2013
    Assignees: HistoRx, Inc., Yale University
    Inventors: Mark Gustavson, Jennifer Giltnane, Marisa P. Dolled-Filhart, Robert L. Camp, David L. Rimm
  • Methods for determining signal transduction activity in tumors
    Patent number: 8367351
    Abstract: The method of the invention pertains to determining the signal transduction activity in a tissue section by immunohistochemistry techniques. The expression level of the receptor of interest is determined as well as the expression levels of one or more effector molecules of the receptor signal transduction pathway. Furthermore a combined ratio of expression levels of effector molecules in subcellular compartments with the receptor expression was found to have prognostic significance.
    Type: Grant
    Filed: May 7, 2007
    Date of Patent: February 5, 2013
    Assignees: Historx, Inc., Yale University
    Inventors: Mark Gustavson, Jennifer Giltnane, Marisa P. Dolled-Filhart, Robert L. Camp, David L. Rimm
  • CORRELATION OF MOLECULAR MARKERS WITH CLINICAL OUTCOME IN GBM PATIENTS RADIATION TREATED WITH OR WITHOUT GEFITINIB
    Publication number: 20100144540
    Abstract: Interestingly, for prognosis, the significant biomarkers for Gefitinib-treated GBM patients (RTOG 0211) appeared to differ compared to historical, RT and non-Gefitinib-treated GBM patients. In Gefitinib-treated patients, those with higher levels of nuclear pAKT driven by PTEN loss, higher levels of nuclear pMAPK, and lower levels of nuclear pmTOR had significantly worse clinical outcomes. In contrast, in non-Gefitinib-treated patients, patients with PTEN-deficiency, and higher levels of EGFRvIII, total EGFR, IGFR1, NFkB and lower levels of nuclear Survivin appeared to have adverse clinical outcomes, highlighting the treatment-dependency of these biomarkers.
    Type: Application
    Filed: September 22, 2009
    Publication date: June 10, 2010
    Inventors: Arnab Chakravarti, Robert Pinard, Donald Waldron, Agnes Ang, Marisa P. Dolled-Filhart, Annette Molinaro, Alpana Waldron
  • SRC ACTIVATION FOR DETERMINING CANCER PROGNOSIS AND AS A TARGET FOR CANCER THERAPY
    Publication number: 20100081666
    Abstract: Methods of cancer diagnosis and prognosis using biomarkers.
    Type: Application
    Filed: July 14, 2009
    Publication date: April 1, 2010
    Applicant: Wyeth
    Inventors: Christina M. COUGHLIN, Michael E. BURCZYNSKI, Marisa P. DOLLED-FILHART, Robert PINARD, Donald WALDROM, Charles ZACHARCHUK, Frederick IMMERMANN, Maha KARNOUB, Jason CHRISTIANSEN, Mark GUSTAVSON, Annette MOLINARO, Alpana Waldron
  • METHODS FOR DETERMINING SIGNAL TRANSDUCTION ACTIVITY IN TUMORS
    Publication number: 20100062452
    Abstract: The method of the invention pertains to determining the signal transduction activity in a tissue section by immunohistochemistry techniques. The expression level of the receptor of interest is determined as well as the expression levels of one or more effector molecules of the receptor signal transduction pathway. Furthermore a combined ratio of expression levels of effector molecules in subcellular compartments with the receptor expression was found to have prognostic significance.
    Type: Application
    Filed: May 7, 2007
    Publication date: March 11, 2010
    Applicants: Yale University, HistoRx, Inc.
    Inventors: Mark Gustavson, Jennifer Giltnane, Marisa P. Dolled-Filhart, Robert L. Camp, David L. Rimm
  • Methods for diagnosing and treating breast cancer based on a HER/ER ratio
    Publication number: 20080153098
    Abstract: Provided are improved, quantitative methods for determining whether a subject is likely to respond to a breast cancer therapy, methods for selecting breast cancer therapies and methods for diagnosis and prognosis of breast cancer in subjects.
    Type: Application
    Filed: December 10, 2007
    Publication date: June 26, 2008
    Inventors: David L. Rimm, Gino Pereira, Malini Harigopal, Jennifer Gitnane, Marisa P. Dolled-Filhart, Robert L. Camp